Lepu Biopharma (HKG:2157) said it will resubmit its new drug application for nasopharyngeal cancer drug MRG003 with necessary supplementary materials to China's National Medical Products Administration on March 4, according to a Tuesday filing with the Hong Kong bourse.

MRG003 is an antibody-drug conjugate that targets EGFR on tumor cells, delivering a potent chemotherapy drug released inside the cell to trigger cancer cell death.

Previously, the NDA application was accepted by the administrator in September 2024 and was later withdrawn by the pharmaceutical company.